Which Country Is Defitelio (Defibrotide Sodium) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Defitelio (defibrotide sodium) is a polydisperse mixture of single-stranded oligonucleotides with endothelial-protective and profibrinolytic activity, used to treat severe hepatic veno-occlusive disease (also called sinusoidal obstruction syndrome) that can occur after haematopoietic stem-cell transplantation. It is supplied as an 80 mg/mL concentrate for solution for infusion in 2.5 mL vials, given intravenously, and it is stored at ambient conditions below 25°C without freezing — there is no 2–8°C cold-chain requirement for this product, which simplifies logistics compared with many other ultra-orphan biologics but does nothing to change who is allowed to dispense it: Defitelio is administered exclusively in the transplant unit that is managing the underlying stem-cell transplant, because the diagnosis itself can only be made and monitored by that team. In Türkiye, TİTCK sets the reference price from the lowest ex-factory price found across a defined basket of EU member states, then converts it using the "pharmaceutical euro" (Dönemsel Avro Değeri) fixed at 65% of the prior year's average Central Bank euro rate rather than the live spot rate — a mechanism published on the TİTCK price list and gazetted in the Resmî Gazete. That structural conversion mechanism, not any discount on the molecule itself, is why Turkish published prices for ultra-orphan hospital biologics sit below those in freely-priced markets.

Germany's AMNOG framework allows the manufacturer, Jazz Pharmaceuticals, to set a free price for the first six months after launch, after which an early-benefit assessment (Frühe Nutzenbewertung) conducted by IQWiG/G-BA leads to a negotiated price applied retroactively from month seven. Because the treated population for hepatic veno-occlusive disease after transplant is extremely small, Defitelio's orphan designation triggers a lighter evidentiary bar under AMNOG — the benefit assessment can rely on smaller single-arm or historically-controlled datasets rather than large randomised trials, since running a randomised trial in a rare, acute, life-threatening condition is rarely feasible. That provision changes the evidence base required, not the currency figure itself. In the United Kingdom, NICE evaluates ultra-orphan hospital medicines partly through its Highly Specialised Technologies route, which applies a more generous cost-per-QALY ceiling than the standard threshold that was raised from £20,000–£30,000 to £25,000–£35,000, announced 1 December 2025 and effective from April 2026 (see NICE). A wider threshold changes what counts as "cost-effective" for a rare, hospital-only condition; it is not a price in itself.

The United States has no government reference-pricing mechanism equivalent to Türkiye's or Germany's for a molecule like defibrotide sodium: the manufacturer sets an opening price freely, and hospital pharmacies negotiate confidential contract terms through group purchasing organisations. The RAND Corporation's 2022 international price comparison, published 1 February 2024, found gross US list prices averaged 278% of prices across 33 other high-income countries for all drugs, and 422% for brand-name originator products specifically — a structural, market-wide gap rather than a figure specific to Defitelio. No generic or biosimilar version of defibrotide sodium exists anywhere: it is a complex polydisperse biological mixture rather than a single defined small molecule, which makes generic substitution technically and regulatorily far harder than for a conventional drug, so there is no patent-cliff price collapse to expect for this product in any market.

Because Defitelio is an ultra-orphan hospital-only product used for a rare, acute complication of stem-cell transplantation, the number of transplant centres worldwide that stock it at all is itself a major driver of the availability and price variation patients encounter — a family cannot simply "shop" for a cheaper country the way they might for an oral chronic-disease medicine, because the drug must be started urgently, in the transplant centre already treating the patient, or not at all. Published national list prices are therefore best read as a reference point for understanding how a given health system funds ultra-rare hospital therapies, not as a shopping price to compare directly. For the underlying mechanics behind Türkiye's published reference prices specifically, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Defitelio I'm being offered genuine?

No falsified batches of Defitelio have been recorded in the WHO's medical product alert series to date. That absence of a documented alert reflects the drug's very limited distribution footprint — it is stocked by a small number of specialist transplant centres worldwide and never enters retail or wholesale channels open to the public — rather than any inherent immunity to diversion or counterfeiting.

Because Defitelio is used only for a life-threatening complication that is diagnosed and managed within the transplant unit itself, the realistic risk for this product is less about street-level counterfeiting and more about confirming that any vial reaching the centre — particularly through cross-border compassionate-use or expanded-access routes — has come from Jazz Pharmaceuticals' authorised hospital-pharmacy supply chain rather than an unverified intermediary, and that its ambient storage conditions have been maintained correctly during transit.

• Scan the carton's GS1 DataMatrix and confirm it decodes correctly to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch/lot) before the vial is accepted by the transplant unit.
• If the vial originates in Türkiye, verify its karekod is registered in the national İlaç Takip Sistemi (İTS) track-and-trace platform at its.saglik.gov.tr before it leaves the dispensing pharmacy.
• Confirm the shipment has been kept at ambient conditions below 25°C and never frozen — Defitelio does not require 2–8°C cold-chain handling, and any vial that has been frozen or exposed to excessive heat should be rejected outright.
• Confirm the hospital pharmacy received the vial directly from an authorised specialty distributor rather than through a courier or private reseller, since Defitelio is not a product legitimately available through retail channels.
• Verify the diagnosis and dosing plan have been confirmed by the treating transplant team, since Defitelio is only ever administered within the unit managing the underlying stem-cell transplant.
• Cross-check the batch number against our WHO falsified medicine alerts tracker as routine practice, even though no Defitelio-specific alert exists at present.
• Review the general verification workflow in our guide to checking that a medicine is genuine before any cross-border sourcing decision is made.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Rare-disease and orphan biologics

Related high-cost medicines